Ligand Pharmaceuticals Incorporated (LGND) Profitability Comparisons, Net Margin, Gross Margin, Tax rate, Cash Flow Margin Comparisons - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Ligand Pharmaceuticals Incorporated  (NASDAQ: LGND)

Ligand Pharmaceuticals Incorporated Profitability Comparisons

Select each Category to receive further Information



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LGND Profitability Ratio

 Company Industry Sector S&P 500
Gross Profit Margin (Q2 MRQ) 87.29 % 70.91 % 67.38 % 46.15 %
Gross Margin (Q2 TTM) 88.85 % 71.7 % 67.8 % 46.36 %
Gross Profit Margin 5 Yr. Avg. 66.72 % 67.81 % 65.55 % 48.95 %
EBITDA Margin (Q2 MRQ) 115.15 % 21.48 % 18.44 % 20.46 %
EBITDA Margin (Q2 TTM) 94.14 % 25.18 % 20.78 % 20.1 %
EBITDA Margin 5 Yr. Avg. 53.24 % 47.09 % 31.38 % 23.41 %
Operating Margin (Q2 MRQ) 13.49 % 17.3 % 16.52 % 16.05 %
Operating Margin (Q2 TTM) 32.61 % 20.35 % 17.83 % 16.34 %
Operating Margin 5 Yr. Avg. 8.18 % 15.37 % 14.33 % 19.26 %
Pre-Tax Profit Margin (Q2 MRQ) 100.96 % 13.68 % 10.72 % 13.96 %
Pre-Tax Profit Margin (Q2 TTM) 81.9 % 16.7 % 12.68 % 13.09 %
Pre-Tax Profit Margin 5 Yr. Avg. 28.94 % 12.98 % 10.37 % 13.52 %
Net Margin (Q2 MRQ) 76.16 % 10.12 % 8.02 % 11.42 %
Net Margin (Q2 TTM) 67.88 % 13.16 % 9.86 % 10.76 %
Net Margin 5 Yr. Avg. 17.47 % 5.79 % 6.08 % 10.8 %



Business Segment Profit Margin
 
Development and Licensing of Biopharmaceutical Assets
  Explore Development and Licensing of Biopharmaceutical Assets Segment  252.01 %
Kyprolis
  Explore Kyprolis Segment  -
Filspari
  Explore Filspari Segment  -
Vaxneuvance
  Explore Vaxneuvance Segment  -
Qarziba
  Explore Qarziba Segment  -
Contract revenue and other income
  Explore Contract revenue and other income Segment  -
Capvaxive
  Explore Capvaxive Segment  -
Ohtuvayre inventors
  Explore Ohtuvayre inventors Segment  -
Contract revenue and income
  Explore Contract revenue and income Segment  -
Intangible Royalty Assets
  Explore Intangible Royalty Assets Segment  -
Financial Royalty Assets
  Explore Financial Royalty Assets Segment  -
Royalty
  Explore Royalty Segment  -
Material Sales, Captisol
  Explore Material Sales, Captisol Segment  -
Royalty Intangible, Other
  Explore Royalty Intangible, Other Segment  -
Contract and Revenue Income, Other
  Explore Contract and Revenue Income, Other Segment  -
 

Company's Cashflow Profitability & Other



Profitability Ratios Company Industry Sector S&P 500
Free Cash Flow Margin (Q2 MRQ) 37.71 % -0.01 % 0.22 % 1.39 %
Free Cash Flow Margin (Q2 TTM) 45.33 % 17.26 % 13.83 % 9.09 %
Free Cash Flow Margin 5 Yr. Avg. - 19.28 % 14.86 % 15.58 %
Net Cash Flow Margin (Q2 MRQ) 0 % 0.02 % -0.02 % 0.13 %
Net Cash Flow Margin (Q2 TTM) 15.35 % -0.67 % 0.15 % 1.85 %
Net Cash Flow Margin 5 Yr. Avg. - 4.38 % 3.16 % 6.44 %
Effective Tax Rate (Q2 MRQ) 24.56 % 25.92 % 25.04 % 18.8 %
Effective Tax Rate (Q2 TTM) 17.12 % 21.21 % 23 % 19.44 %
Effective Tax Rate 5 Yr. Avg. 78.2 % 15.08 % 20.51 % 19.76 %
Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.